FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours ner response	0.5

✓ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person* ALTA BIOPHARMA PARTNERS III LP			2. Issuer Name and Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title below) X Other (specify below)					
ONE EM		(First) DERO CENTER,		3. Date of 10/05/2			ransact	ion (Mon	th/Day/	Year)			For	ner 10% owr	er	
SAN FR	ANCISCO	(Street)		4. If Am	endn	ment, Da	nte Ori	ginal Filed	d(Month/I	Day/Year)	_	Form filed by	y One Reporting	up Filing(Chec Person e Reporting Perso		ine)
(Cit	y)	(State)	(Zip)			[Fable 1	I - Non-D	erivativ	e Securit	ies Acquir	ed, Dispose	d of, or Ben	eficially Owr	ied	
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)	2A. Dec Executi any (Month	on D	Date, if		8)	(A) or	Disposed 3, 4 and 5	of (D)	5. Amount of Securities Beneficia Owned Following Reported Transaction(s) (Instr. 3 and 4)		ed	6. Ownership Form: Direct (D) or Indirect (I)	Beneficial Ownership
Common	n Stock		10/05/2009				Cod	le V	Amou 239,7	int (D)	Price \$	1,439,921			(Instr. 4) D (1) (2)	
Common			10/05/2009				P		16,10		1.91	96,704				See footnotes (2) (3)
Common	ı Stock		10/05/2009				P		5,909	A	\$ 1.91	35,485			I	See footnotes (2) (4)
Reminder:	Report on a s	separate line for each		· Derivat	ive S	Securiti	es Acq	Pers in th disp	ons wl is form lays a	are not currently	required valid Of	to respond MB control	d unless th	tion contai e form	ned SEC	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	tion	5. Nun	nber ivative ries red (A) posed	6. Date I Expiration	Exercisa on Date			es		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	Owners Form of Derivati Security Direct (or Indire	Ownershi (Instr. 4)
				Code	V	(A)	(D)	Date Exercisa		piration te	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4	
Warrant	\$ 2.23	10/05/2009		P		95,90	7	<u>(5)</u>	10	/05/2014	Comm Stock		\$ 0 (6)	499,987	D (1)	(2)
Warrant	\$ 2.23	10/05/2009		P		6,441	Í	<u>(5)</u>	10.	/05/2014	Comm Stock	n 44 i	\$ 0 ⁽⁶⁾	33,578	I	See footnote (2) (3)
Warrant	\$ 2.23	10/05/2009		P		2,363	3	(5)	10.	/05/2014	Comm Stock	7 262	\$ 0 (6)	12,321	I	See footnote (2) (4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
ALTA BIOPHARMA PARTNERS III LP ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO, CA 94111				Former 10% owner		

ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO, CA 94111		Former 10% owner
ALTA BIOPHARMA MANAGEMENT III LLC ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO, CA 94111		Former 10% owner
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO, CA 94111		Former 10% owner
DELEAGE JEAN ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94111		Former 10% owner
CHAMPSI FARAH ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94132		Former 10% owner
PENHOET EDWARD ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94111		Former 10% owner
HURWITZ EDWARD ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO, CA 94111		Former 10% owner

Signatures

By Alta BioPharma Management III, LLC, /s/ Jean Deleage, Director	10/06/200
**Signature of Reporting Person	Date
Alta BioPharma Management III, LLC, It's General Partner, /s/ Jean Deleage, Director	10/06/200
**Signature of Reporting Person	Date
/s/ Jean Deleage, Director	10/06/200
**Signature of Reporting Person	Date
/s/ Jean Deleage, Manager	10/06/200
^{**} Signature of Reporting Person	Date
/s/ Jean Deleage	10/06/200
—Signature of Reporting Person	Date
/s/ Farah Champsi	10/06/200
**Signature of Reporting Person	Date
/s/ Edward Penhoet	10/06/200
[→] Signature of Reporting Person	Date
/s/ Edward Hurwitz	10/06/200
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are held of record by Alta BioPharma Partners III, L.P.("ABPIII").
- Alta BioPharma Management III, LLC ("ABMIII") is the General Partner of ABPIII and Managing Limited Partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG
- (2) ("ABPIIIKG"). Jean Deleage, Farah Champsi, Edward Penhoet, and Edward Hurwitz are directors of ABMIII and managers of Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII" and, along with ABPIII and ABPIIIKG, the "Funds") and they exercise shared voting and investment power with respect to the shares owned by the Funds. Each reporting persons disclaims beneficial ownership of such securities, except to the extend of his or her pecuniary interest therein.
- (3) These securities are held of record by ABPIIIKG.
- (4) These securities are held of record by AEBPIII.
- (5) These warrants are immediately exercisable.
- These warrants were issued pursuant to Securities Purchase Agreement ("SPA") dated September 29, 2009. For every share of stock purchased at \$1.91 according to the SPA, 0.4 share of

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.